Plus Therapeutics, Inc. (NASDAQ:PSTV) Sees Large Increase in Short Interest

Plus Therapeutics, Inc. (NASDAQ:PSTV) saw a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 52,700 shares, a growth of 51.0% from the August 31st total of 34,900 shares. Based on an average trading volume of 54,300 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.9% of the shares of the stock are sold short.

Institutional Trading of Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC purchased a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned about 9.98% of Plus Therapeutics at the end of the most recent reporting period. 3.28% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PSTV has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Plus Therapeutics in a report on Friday, August 16th. Ascendiant Capital Markets decreased their price target on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd.

Plus Therapeutics Trading Up 20.1 %

Shares of PSTV traded up $0.31 during trading hours on Friday, reaching $1.85. 370,333 shares of the company’s stock traded hands, compared to its average volume of 56,610. Plus Therapeutics has a 12 month low of $0.97 and a 12 month high of $2.78. The stock has a market cap of $10.55 million, a PE ratio of -0.61 and a beta of 0.65. The firm’s 50 day simple moving average is $1.55 and its 200-day simple moving average is $1.78.

Plus Therapeutics (NASDAQ:PSTV) last announced its earnings results on Wednesday, August 14th. The company reported ($0.71) earnings per share (EPS) for the quarter. Plus Therapeutics had a negative net margin of 240.15% and a negative return on equity of 805.57%. The company had revenue of $1.28 million for the quarter. As a group, analysts expect that Plus Therapeutics will post -2.22 earnings per share for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.